Compare ABUS & YELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | YELP |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2008 | 2011 |
| Metric | ABUS | YELP |
|---|---|---|
| Price | $4.69 | $18.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $29.17 |
| AVG Volume (30 Days) | ★ 4.7M | 1.2M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | 19.15 |
| EPS | 0.84 | ★ 0.86 |
| Revenue | $14,083,000.00 | ★ $1,464,955,000.00 |
| Revenue This Year | N/A | $2.19 |
| Revenue Next Year | $239.71 | $2.34 |
| P/E Ratio | ★ $5.71 | $20.67 |
| Revenue Growth | ★ 128.21 | 3.75 |
| 52 Week Low | $3.50 | $17.27 |
| 52 Week High | $5.45 | $34.49 |
| Indicator | ABUS | YELP |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 28.56 |
| Support Level | $4.42 | N/A |
| Resistance Level | $4.81 | $24.91 |
| Average True Range (ATR) | 0.09 | 0.73 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 16.48 | 10.52 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.